Foghorn Therapeutics (FHTX) Share-based Compensation (2019 - 2026)

Foghorn Therapeutics' Share-based Compensation history runs 8 years deep, the most recent figure standing at $2.4 million for Q1 2026.

• On a quarterly basis, Share-based Compensation fell 11.48% year-over-year to $2.4 million in Q1 2026; TTM through Mar 2026 was $10.1 million, a 11.19% decrease from a year earlier, with the FY2025 full-year figure at $10.4 million, down 12.56% from the prior year.
• Share-based Compensation rose to $2.4 million in Q1 2026 per FHTX's latest filing, from $2.2 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $4.6 million in Q1 2023 and bottomed at $2.2 million in Q4 2025.
• The 5-year median for Share-based Compensation is $3.2 million (2024), against an average of $3.2 million.
• Across the five-year window, Share-based Compensation soared 81.43% in 2022 and decreased 29.48% in 2024, its largest moves.
• Year by year, Share-based Compensation stood at $3.8 million in 2022, then declined by 19.31% to $3.1 million in 2023, then declined by 18.62% to $2.5 million in 2024, then decreased by 9.75% to $2.2 million in 2025, then advanced by 6.34% to $2.4 million in 2026.
• Per Business Quant, the three latest FHTX Share-based Compensation figures stand at $2.4 million (Q1 2026), $2.2 million (Q4 2025), and $2.7 million (Q3 2025).